

Striving for Consensus: Optimizing the Selection and Sequencing of Therapy for Patients with Relapsed/Refractory Follicular Lymphoma — Part 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase II ROSEWOOD study evaluating the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone for relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with 2 or more prior regimens reported what major efficacy outcomes?
 - a. Inferior overall response rate (ORR) and progression-free survival (PFS) with zanubrutinib and obinutuzumab
 - b. No significant difference in ORR or PFS with zanubrutinib and obinutuzumab
 - c. A significant improvement in ORR and PFS with zanubrutinib and obinutuzumab
2. In the FL cohort of the ongoing Phase III MAHOGANY trial, what is the therapeutic intervention that is being compared to lenalidomide and rituximab (R²) for R/R FL previously treated with 1 or more prior lines of systemic therapy?
 - a. Ibrutinib with rituximab
 - b. Zanubrutinib with obinutuzumab
 - c. Tafasitamab with R²
 - d. Loncastuximab tesirine with rituximab
3. The Phase III inMIND study of tafasitamab and R² versus R² alone for R/R FL previously treated with 1 or more prior lines of systemic therapy reported what major efficacy outcome?
 - a. No significant difference in PFS with tafasitamab and R²
 - b. A nonsignificant numerical PFS trend favoring tafasitamab and R²
 - c. A statistically significant improvement in PFS with tafasitamab and R²
4. What is the mechanism of action of tazemetostat?
 - a. CD19 inhibitor
 - b. CD20 inhibitor
 - c. EZH2 inhibitor
 - d. Bruton tyrosine kinase inhibitor
5. In the Phase III inMIND study of tafasitamab and R² versus R² alone for R/R FL previously treated with 1 or more prior lines of systemic therapy, what was the approximate ORR for patients who received tafasitamab and R²?
 - a. 21%
 - b. 45%
 - c. 60%
 - d. 83%